Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NewLink Genetics (Ebola vaccine)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Portfolio of Ebola vaccine. The vaccine candidate, called rVSV-EBOV, was originally developed by the Public Health Agency of Canada. It is currently being evaluated in phase-I clinical trials.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Buildings and Property
Acquirer
Primary Office
  • Ames, IA
  • United States

NewLink Genetics (Ebola vaccine) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.

Request full access to PitchBook

NewLink Genetics (Ebola vaccine) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.

Request full access to PitchBook